Think of Enterprise Value as the theoretical takeover price. It is more comprehensive than market capitalization (Market Cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.
EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Genscript Biotech's Enterprise Value is HK$14,571 Mil.
Genscript Biotech's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 was HK$-2,532 Mil. Therefore, Genscript Biotech's EV-to-EBIT ratio for today is -5.76.
EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA. As of today, Genscript Biotech's Enterprise Value is HK$14,571 Mil.
Genscript Biotech's EBITDA for the trailing twelve months (TTM) ended in Dec. 2023 was HK$-1,953 Mil. Therefore, Genscript Biotech's EV-to-EBITDA ratio for today is -7.46.
EV-to-Revenue is calculated as Enterprise Value divided by its Revenue. As of today, Genscript Biotech's Enterprise Value is HK$14,571 Mil.
Genscript Biotech's Revenue for the trailing twelve months (TTM) ended in Dec. 2023 was HK$6,566 Mil. Therefore, Genscript Biotech's EV-to-Revenue ratio for today is 2.22.
Genscript Biotech Enterprise Value Historical Data
The historical data trend for Genscript Biotech's Enterprise Value can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Genscript Biotech's Enterprise Value
For the Biotechnology subindustry, Genscript Biotech's Enterprise Value, along with its competitors' market caps and Enterprise Value data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Genscript Biotech's Enterprise Value Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Genscript Biotech's Enterprise Value distribution charts can be found below:
* The bar in red indicates where Genscript Biotech's Enterprise Value falls into.
Genscript Biotech Enterprise Value Calculation
Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.
Genscript Biotech's Enterprise Value for the fiscal year that ended in Dec. 2023 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Genscript Biotech (HKSE:01548) Enterprise Value Explanation
When an investor buy a company, the investor needs to pay not only the common shares, he/she also needs to pay the shareholders of Preferred Stocks. He also assumes the debt of the company, and receives the cash on the company's balance sheet.
If a company has more cash than debt, the investor actually pays less than the Market Cap because he immediately owns the cash once the transaction goes through.
The market value of Preferred Stock needs to be added to the market value of common stocks in the calculation of Enterprise Value.
For the companies with the same Market Cap, the smaller the Enterprise Value is, the cheaper the company is.
Enterprise Value can be negative when the company's net cash is more than its Market Cap. In this case the investor is basically getting the company for free and get paid for that.
1. EV-to-EBIT is calculated as Enterprise Value divided by its EBIT.
Genscript Biotech's current Enterprise Value is HK$14,571 Mil.
For company reported semi-annually or annually, GuruFocus uses latest annual data as the TTM data. Genscript Biotech's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 was HK$-2,532 Mil.
2. EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA.
Genscript Biotech's current Enterprise Value is HK$14,571 Mil.
For company reported semi-annually or annually, GuruFocus uses latest annual data as the TTM data. Genscript Biotech's EBITDA for the trailing twelve months (TTM) ended in Dec. 2023 was HK$-1,953 Mil.
Genscript Biotech's current Enterprise Value is HK$14,571 Mil.
For company reported semi-annually or annually, GuruFocus uses latest annual data as the TTM data. Genscript Biotech's Revenue for the trailing twelve months (TTM) ended in Dec. 2023 was HK$6,566 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Genscript Biotech Enterprise Value Related Terms
Thank you for viewing the detailed overview of Genscript Biotech's Enterprise Value provided by GuruFocus.com. Please click on the following links to see related term pages.
Genscript Biotech (HKSE:01548) Business Description
GenScript Biotech is a China-based provider of life science research services and products. Founded in 2002, it is best known for its gene synthesis capabilities, a widely used service by academics, biotech companies, and pharmaceutical companies around the world. Its business lines include life science research services and products, biologics development services under its ProBio brand, and industrial enzymes under its Bestzyme brand. Finally, it owns 57.1% of Nasdaq-listed Legend Biotech, whose key pipeline asset is a BCMA-targeting CAR-T treatment for multiple myeloma. We estimate that more than two thirds of GenScript's valuation is from its ownership stake in Legend.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
HKSE:01548 has been successfully added to your 